Posts by Hiroaki Nagashima, MD, PhD
-
Novel Combination Therapy Highly Effective Against IDH-mutant Glioma
Adding a poly(ADP-ribose) glycohydrolase inhibitor to temozolomide was highly effective in glioma cell lines and an IDH-mutant xenograft mouse model.
Biography
Dr. Nagashima is a post-doctoral fellow in the Cahill Lab at Massachusetts General Hospital. He attended Toyama University where he received his MD degree in 2007; completed neurosurgery residency training at Kobe University Hospital in 2013; and received a PhD from Kobe University in 2016. His research goal is to develop novel therapy and diagnostic biomarker for IDH mutant glioma by using metabolomic approaches.
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.